{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443208622
| IUPAC_name = ''N''-(4,5-Dihydro-1''H''-imidazol-2-ylmethyl)-''N''-(phenylmethyl)aniline
| image = Antazoline.svg
| width = 215

<!--Clinical data-->
| tradename = Vasocon-a
| Drugs.com = {{drugs.com|CONS|vasocon-a}}
| routes_of_administration = Topical (nasal, [[eye drop]]s)

<!--Identifiers-->
| IUPHAR_ligand = 7116
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 91-75-8
| ATC_prefix = R01
| ATC_suffix = AC04
| ATC_supplemental = {{ATC|R06|AX05}}
| PubChem = 2200
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08799
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 84115
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2115
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = DHA8014SS1
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07458
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1305

<!--Chemical data-->
| C=17 | H=19 | N=3 
| molecular_weight = 265.353 g/mol
| smiles = N\1=C(\NCC/1)CN(c2ccccc2)Cc3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = REYFJDPCWQRWAA-UHFFFAOYSA-N
}}

'''Antazoline''' is a 1st generation [[antihistamine]] with [[anticholinergic]] properties used to relieve [[nasal congestion]] and in [[eye drop]]s, usually in combination with [[naphazoline]], to relieve the symptoms of [[allergy|allergic]] [[conjunctivitis]].<ref>{{cite journal |journal = Am J Ophthalmol |year = 1980 |volume =90 |pages = 254–7 |title = Effects of topically applied ocular decongestant and antihistamine |vauthors=Abelson MB, Allansmith MR, Friedlaender MH |pmid=7425039 |issue=2 |doi=10.1016/s0002-9394(14)74864-0}}</ref> To treat allergic conjunctivitis, antazoline can be combined in a solution with [[tetryzoline]].<ref name="Castillo">{{cite journal |authors=Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A |title= Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis |journal=Cochrane Database Syst Rev|volume=6 |pages= CD009566 |date=2015 |pmid= 26028608 |doi= 10.1002/14651858.CD009566.pub2}}</ref> The drug is a [[Histamine H1 receptor]] antagonist:<ref>{{Cite journal|last=Noguchi|first=Seiji|last2=Inukai|first2=Toshiya|last3=Kuno|first3=Takayoshi|last4=Tanaka|first4=Chikako|title=The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking|journal=Physiology & Behavior|volume=51|issue=6|pages=1123–1127|doi=10.1016/0031-9384(92)90297-f|pmid=1353628|date=June 1992}}</ref> selectively binding to but not activating the receptor, thereby blocking the actions of endogenous [[histamine]] and subsequently leading to the temporary relief of the negative symptoms brought on by histamine.

== References ==
{{Reflist|1}}

{{Nasal preparations}}
{{Antihistamines}}
{{Cholinergics}}
{{Histaminergics}}

[[Category:H1 receptor antagonists]]
[[Category:Imidazolines]]


{{respiratory-system-drug-stub}}